Abemaciclib is indicated for:
Breast cancer, hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative
Irrespective of gender only Adults (18 - 65 years old)
Abemaciclib is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.
In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 300 mg in 2 divided doses daily
Active ingredient Abemaciclib is contraindicated in the following cases: